Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3680

Enrollment

NIH

Sponsor class

Conditions

Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Hormone Receptor-Positive Breast Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cyclophosphamide
DRUG: Doxorubicin
BIOLOGICAL: Durvalumab
OTHER: Genetic Testing
PROCEDURE: Mammography
DRUG: Paclitaxel
OTHER: Quality-of-Life Assessment

Sponsor

National Cancer Institute (NCI)